AlphAIAlphAI — Financial news for AI agents
mychesco.comAUG 183 min read$IPSC

Century Targets FDA Filing for Diabetes Cell Therapy

Century Therapeutics (NASDAQ: IPSC) aims to file for FDA approval of its diabetes cell therapy, CNTY-813, in Q4 2026, with initial human data expected in 2027. The company reported $197.2M in cash as of Q2 2026, sufficient to fund operations into Q1 2029. Preclinical results showed promising glucose control and immune evasion, but clinical outcomes are not guaranteed. Century also advances CNTY-308, a CAR-iT cell therapy, with IND-enabling work on track for 2026. Q2 R&D expenses decreased 27% to

Original reporting
mychesco.com
Published Aug 18, 2026, 10:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 8:21 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Century Targets FDA Filing for Diabetes Cell Therapy — source image
Source · mychesco.com
Decision brief

The 30-second read

$IPSCBullishHigh
01

Why it matters

The announcement provides a concrete catalyst timeline, likely influencing investor sentiment and valuation of the company and peers.

02

Market read

Regulatory progress for a novel diabetes therapy creates a near‑term trading opportunity and may affect sector sentiment.

03

What to watch

Execution risk of manufacturing scale‑up and competition from other cell‑therapy programs.

Relevance 8/10Novelty 8/10Timing: Q4 2026 filing target

Background

Century Therapeutics reported Q2 results and disclosed its regulatory timeline for CNTY-813, a stem‑cell derived islet therapy for type 1 diabetes.

Company-level read

Ticker impact

$IPSCBullishHigh confidence
Context

Century Therapeutics announced it aims to file an FDA IND for its CNTY-813 cell therapy in Q4 2026, marking the first public timeline for the program.

Expected impact

Upward pressure if filing stays on schedule; possible short-term rally on news.

Evidence & confidence

First disclosure of filing timeline, backed by cash runway and pre-IND meeting agreement, suggests reduced execution risk.

Market effects

Sector

Strengthens outlook for the cell‑therapy sector and may boost related biotech stocks.

Regional

Positive for U.S. biotech investors; limited immediate global effect.

Global

Highlights continued US regulatory progress in advanced therapies.

Counterpoint

What could challenge this read

If the IND filing is delayed, the stock could face disappointment and sell‑off.

Key entities

  • Company
    Century Therapeutics, Inc.

    Biotech developing cell‑based therapies for diabetes.

  • Regulator
    FDA

    U.S. Food and Drug Administration overseeing IND submission.

Read at source← All news

Related articles

OCT 2
$IPSCMedAI 8/10

Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026

Century Therapeutics, Inc. (IPSC) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026 Data demonstrated scalable production, in vivo function and immune evasion, and updated progress toward clinical dosing of CNTY-813, Centur

SEC EDGAR 8-K2 min
OCT 2
$IPSCMedAI 8/10

Century Therapeutics presents diabetes therapy data at EASD

Century Therapeutics (NASDAQ:IPSC) presented data on CNTY-813, a diabetes therapy, at the EASD meeting. The therapy showed long-term glycemic control in mouse models and successful engraftment in rats. The company plans to submit an IND application in Q4 2026, with clinical data expected in H2 2027, according to the press release.

investing.com2 min
OCT 2
$IPSCMed

Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026

Century Therapeutics (NASDAQ: IPSC) presented nonclinical data for CNTY-813, its iPSC-derived islet replacement therapy for type 1 diabetes, at EASD 2026. Data showed glycemic control in diabetic mice, scalable production, and immune evasion. The company expects to submit an IND application in Q4 2026 and anticipates initial clinical data in 2H 2027.

globenewswire.com3 min
AUG 12
$IPSCMed

Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

Century Therapeutics, Inc. (IPSC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates · Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track f

SEC EDGAR 8-K5 min